drugset
drugset / Trial / NCT05769855

A Study of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

NCT05769855 ↗

Phase 3 Completed 294 enrolled Shanghai Hengrui Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is being conducted to evaluate the efficacy, and safety of HR18034 for postoperative analgesia in subjects undergoing hemorrhoidectomy.

Timeline

Start
2023-03-21
Primary completion
2023-10-30
Completion
2023-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HR18034 Unknown 380 mg Other
Comparator Ropivacaine Other / unclassified 75 mg —

Indications

No indication recorded.